30 closest matches · ranked by relevance
Cardiovascular Diseases · Coronary Disease · Heart Failure, Congestive
Primary: H01: All Cause Mortality — 244; 218 participants — p=0.12
Coronary Artery Bypass Grafting
Primary: Incidence of First MACE During Active Follow-up Period. — 80; 89 Participants — p=0.47
Ischemic Heart Disease
Primary: Short-term End Point — 61; 77 participants
Atrial Septal Defect
Primary: Number of Participants Who Experienced Adverse Events Possibly Related to Study Intervention — 0; 6 Participants
Coronary Artery Disease
Primary: Accuracy (FTF Decision on Patient Disposition vs. V-visit Decision on Patient Disposition) — 89 percentage of agreement
Cardiac Surgical Procedures · Hemorrhage
Primary: Time to Hemostasis (TTH) — 1.50; 3.00 minutes
Robotic Cardiac Surgery Simulation
Primary: Time-based Score — 553; 127; 143 score on a scale
Reperfusion Injury
Primary: Mortality — 0; 0 participants
Shock · Cardiovascular Diseases · Critical Illness
Primary: Perfused Vessel Denisty (PVD) — 22.8; 23.8; 20.2; 22.5 mm/mm^2
Anemia · Hematologic Diseases · Cardiovascular Diseases
Primary: Inability to Walk 10 Feet or Across a Room Without Human Assistance or Death — 351; 347 participants
Haemorrhage · Haemostasis · Cardiovascular Surgery
Primary: Proportion of Subjects Achieving Haemostasis at 3 Minutes — 0.746; 0.333 Proportion of Subjects — p=<0.0001
Arteriosclerosis of Coronary Artery Bypass Graft
Primary: Technical Success (Graft Patency) in a MICS Approach — 100 percentage of grafts
Acute Lung Injury · Sepsis · Infections
Primary: Acute Lung Injury After Cardiac Surgery — 20 participants — p=<0.05
Reduction of Length of Hospitality Stay, Reduction of Perioperative Complications
Primary: Postoperative Complications — 52; 72 numbers of complications
Thoracic Surgery · Cardiopulmonary Bypass
Primary: Composite Neurological Outcome of Clinical Stroke or New Ischemic Brain Lesion on Diffusion Weighted MRI or Neurocognitive Dysfunction 4 to 6 Weeks After Surgery. — 79…
Atrial Fibrillation
Primary: Incidence of Postoperative Atrial Fibrillation — 5; 4; 5 participants
Peripheral Arterial Disease · Vascular Surgery
Primary: Troponin I Elevation Above the Upper Reference Limit (URL) — 25; 22 participants
Mitral Regurgitation
Primary: Number of Participants With Major Serious Adverse Events and Serious Adverse Device Effects — 2; 1; 2; 4 Participants
Aortic Valve Stenosis · Aortic Valve Stenosis With Insufficiency · Regurgitation, Aortic Valve
Primary: Number of Late Adverse Events Divided by Late Patient Years (Expressed as a Percentage) for the INTUTY Valve Implanted Cohort — 3.9; 0.9; 0.6; 0.3 Percentage of…
Aortic Valve Disease · Mitral Valve Disease
Primary: Intraoperative and Postoperative Transfusions — 2.43; 2.97; 4.42; 3.50 units of blood per participant — p=0.354
Atrial Fibrillation New Onset
Primary: Primary Safety Endpoint — 3.9; 3.6 percentage of participants
Aortic Valve Stenosis With Insufficiency · Aortic Valve Stenosis
Primary: Percent of Early Adverse Events — 1.7; 1.0; 4.5; 0.0 Percentage of subjects
Cardiac Surgery
Primary: Intraoperative Systemic Oxidative Damage — 69; 83 pg/ml
Coronary Artery Disease
Primary: Myocardial Defect Perfusion — 15.76; 15.38; 2.08; 3.85 Percentage of Myocardial Perfusion
Heart Diseases · Coronary Artery Disease · Chest Pain
Primary: Enrollment and Randomization Feasibility — 40 Participants
Cardiovascular Disease
Primary: Hemostasis at the Target Bleeding Site (TBS) at 3 Minutes Following Treatment Application. — 12; 6; 5 Participants
Cardiovascular Disease · Peripheral Artery Disease · Critical Limb Ischemia
Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants
Coronary Artery Bypass Grafting
Primary: Ease of Use — 4; 1 units on a scale
Patients Waiting for Coronary Artery Bypass Graft Surgery · Patients Waiting for Aortic Valve Repair or Replacement · Patients Waiting for Mitral Valve Repair or Replacement
Primary: Proportion of Patients With Hospital Length of Stay Greater Than 7 Days. — 20; 16 Participants
Tricuspid Valve Insufficiency · Tricuspid Regurgitation · Tricuspid Valve Regurgitation
Primary: Major Serious Adverse Events (MSAEs) and Serious Adverse Device Effects (SADE) — 3; 1 Participants